Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 36 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo 70 mg/mL Clear all

Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Interventions: Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo; Biological · Drug
Lead sponsor: Beijing Luzhu Biotechnology Co., Ltd.; Other
Eligibility: 50 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Colchicine, Inflammation in Cardiac Surgery, Post Operative Atrial Fibrillation, Inflammatory Markers, Colchicine Adverse Reaction
Interventions: Colchicine (Colcrys®), Placebo; Drug
Lead sponsor: Ayesha Ather; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Urothelial Carcinoma
Interventions: Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 18
States / cities: Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more

Conditions: Cardiovascular Diseases in Old Age
Interventions: BRJ Nitrate, BRJ Placebo; Dietary Supplement
Lead sponsor: Wake Forest University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Respiratory Failure
Interventions: Nitrate Rich Beetroot Juice, Placebo; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 56 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy Volunteers, Asthma
Interventions: melrilimab (GSK3772847) 70 milligram (mg), melrilimab (GSK3772847) 140 milligram (mg), Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Rosuvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 54
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more

Conditions: HIV Infection
Interventions: Alendronate, Placebo, Calcium carbonate/vitamin D; Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 11 Years to 24 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Lancaster, California • Ventura, California • Walnut Creek, California + 9 more

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Arterial Catheterization
Interventions: Lidocaine/tetracaine patch, Placebo Patch, Subcutaneous injection of 0.5 ml Lidocain 1%, Subcutaneous injection of saline; Drug
Lead sponsor: Medical University of Vienna; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Migraine or Episodic Migraine
Interventions: Placebo, AMG 301; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more

Search by objective public record fields.

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Colchicine's Effect on Inflammatory Markers

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Efficacy Long-term Dietary Nitrate Consumption to Plasma Nitrite Conversion

Strength Testing After Nitrate Delivery (STAND) in ICU Patients

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Rapydan Topical Anaesthesia for Arterial Cannulation

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention